European clinical practice guidelines on the use of chemotherapy for advanced oesophageal and gastric cancers: a critical review using the AGREE II and the AGREE-REX instruments
-
Marilina Santero [2] ; Adriana Gabriela Meade [2] ; Roberto Acosta-Dighero [1] ; Lucas González [3] ; Santiago Melendi [4] ; Ivan Solà [2] ; Gerard Urrútia [2] ; Maria Jesús Quintana [2] ; Xavier Bonfill Cosp [2]
-
[1] Universidad San Sebastián
Universidad San Sebastián
Comuna de Concepción, Chile
-
[2] Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona
-
[3] Hospital Prof Dr Rodolfo Rossi, La Plata, Argentina
-
[4] Hospital General de Agudos Carlos G. Durand, Buenos Aires, Argentina
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 8, 2022, págs. 1588-1604
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose To assess the methodological quality of all relevant and recent European clinical practice guidelines (CPGs) for advanced oesophageal and gastric cancers, and to synthesise their recommendations on the use of chemotherapy.
Methods We searched PubMed, EMBASE, guidelines repositories, and other sources from 2010 onwards. We appraised quality using AGREE-II and AGREE-REX.
Results 11 CPGs were included (five high, five low, and one moderate quality). Most guidelines showed deficiencies in the domain “applicability”, with only three scoring above 60%. Nine did not report having sought the views and preferences of the target population. The lowest scores for AGREE-REX were item Values and Preferences of Target Users (1.6; SD 1.3), and item Values and Preferences of Policy/Decision-Makers (1.8; SD 1.7). The domain Clinical Applicability got the highest score and the domain Implementability got the lowest.
Conclusions An urgent area of research is how to develop credible and implementable recommendations on the clinical use of CT for advanced oesophageal and gastric cancer. Systematic review registration: PROSPERO (CRD42021236753).
